113336-22-4 Usage
General Description
1H-pyrazol-1-ylacetonitrile, also identified by its IUPAC name as 1-(3-cyanopropyl)-1H-pyrazole, is a chemical compound of scientific interest. Specific details, such as its molecular weight, structure, boiling and melting points are available in dedicated chemical databases used by researchers, including ChemSpider, PubChem, and others, for references. It is commonly used as a reagent in chemical and biochemical reactions due to its stable structure and reactivity. Like any chemical, it needs to be handled appropriately to prevent safety hazards, and its physicochemical properties are important factors when designing and performing experiments.
Check Digit Verification of cas no
The CAS Registry Mumber 113336-22-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,3,3,3 and 6 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 113336-22:
(8*1)+(7*1)+(6*3)+(5*3)+(4*3)+(3*6)+(2*2)+(1*2)=84
84 % 10 = 4
So 113336-22-4 is a valid CAS Registry Number.
InChI:InChI=1/C5H5N3/c6-2-5-8-4-1-3-7-8/h1,3-4H,5H2
113336-22-4Relevant articles and documents
Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2)
Pei, Zhonghua,Mendonca, Rohan,Gazzard, Lewis,Pastor, Richard,Goon, Leanne,Gustafson, Amy,Vanderporten, Erica,Hatzivassiliou, Georgia,Dement, Kevin,Cass, Robert,Yuen, Po-Wai,Zhang, Yamin,Wu, Guosheng,Lin, Xingyu,Liu, Yichin,Sellers, Benjamin D.
, p. 417 - 421 (2018)
Tryptophan 2,3-dioxygenase 2 (TDO2) catalyzes the conversion of tryptophan to the immunosuppressive metabolite kynurenine. TDO2 overexpression has been observed in a number of cancers; therefore, TDO inhibition may be a useful therapeutic intervention for
PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS
-
Page/Page column 46; 47, (2015/07/15)
Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.
KINASE INHIBITORS
-
Paragraph 0466; 0467, (2013/03/26)
Methods of inhibiting kinases using kinase inhibitors having olefin moieties are disclosed.
